ResMed Inc (RMD)
ResMed Inc (RMD) carries a ŷRobot AI score of 63 out of 100. The model's fair value estimate is $237.90, 4.9% above the last close of $226.75. The chart signal reads Sell.
| Metric | RMD |
|---|---|
| AI score | 63 / 100 |
| Chart signal | Sell |
| Fair value estimate | $237.90 |
| Upside to fair value | 4.9% |
| Previous close | $226.75 |
| P/E | 21.18 |
| Price / sales | 5.64 |
| Market cap | $31.04B |
| EPS | 10.44 |
| Revenue growth | 9.6% |
| 1-year price change | -0.6% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about RMD
Is RMD overvalued or undervalued right now?
As of Oct 8, 2026, ŷRobot's fair-value model estimates ResMed Inc (RMD) at $237.90 against a last close of $226.75, implying 4.9% upside to the model's estimate.
Is RMD's chart signal bullish or bearish?
The chart-signal model classifies RMD as Bearish as of Oct 8, 2026, with a signal score of -0.15 on a -1 to 1 scale.
What is RMD's ŷRobot AI score?
RMD scores 63 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 8, 2026.
Is RMD stock expensive on P/E and P/S?
RMD trades at 21.2 times earnings and 5.6 times sales as of Oct 8, 2026.
What does RMD's seasonal forecast show?
ŷRobot's seasonal forecast curve for RMD reads -0.2% at 30 days, +1.8% at 90 days, and -0.6% at one year as of Oct 8, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is RMD growing?
ResMed Inc's revenue growth is +9.6% and free-cash-flow growth is +4.5% on the latest reported figures.
RMD chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.